{"id":2326,"date":"2025-11-26T09:35:00","date_gmt":"2025-11-26T08:35:00","guid":{"rendered":"https:\/\/semmelweis.hu\/esk\/?p=2326"},"modified":"2025-12-04T09:35:25","modified_gmt":"2025-12-04T08:35:25","slug":"a-covid-19-vedooltasok-eredmenyessege-a-korhazi-kezelest-igenylo-megbetegedesek-megelozeseben-az-idosebb-felnottek-koreben","status":"publish","type":"post","link":"https:\/\/semmelweis.hu\/esk\/2025\/11\/26\/a-covid-19-vedooltasok-eredmenyessege-a-korhazi-kezelest-igenylo-megbetegedesek-megelozeseben-az-idosebb-felnottek-koreben\/","title":{"rendered":"A Covid-19 v\u00e9d\u0151olt\u00e1sok eredm\u00e9nyess\u00e9ge a k\u00f3rh\u00e1zi kezel\u00e9st ig\u00e9nyl\u0151 megbeteged\u00e9sek megel\u0151z\u00e9s\u00e9ben az id\u0151sebb feln\u0151ttek k\u00f6r\u00e9ben"},"content":{"rendered":"
VEBIS* k\u00f3rh\u00e1zi h\u00e1l\u00f3zat, Eur\u00f3pa, 2024. szeptember \u2013 2025. m\u00e1jus<\/strong><\/h5>\n

2024. \u0151sz\u00e9n a 60 \u00e9v felettiek \u00e9s m\u00e1s magas kock\u00e1zat\u00fa c\u00e9lcsoportok Covid-19 elleni v\u00e9delm\u00e9re olt\u00e1si kamp\u00e1nyokat ind\u00edtottak Eur\u00f3p\u00e1ban. Els\u0151dleges olt\u00f3anyagk\u00e9nt ebben az id\u0151szakban a Comirnaty Omikron JN.1 vakcin\u00e1j\u00e1t alkalmazt\u00e1k, ezzel a c\u00e9lcsoportok \u00e1toltotts\u00e1ga az egyes orsz\u00e1gokban alacsony, m\u00edg m\u00e1shol k\u00f6zepes volt. A szezon sor\u00e1n a SARS\u2011CoV\u20112 aktivit\u00e1sa a kor\u00e1bbi \u00e9vekhez k\u00e9pest alacsonyabb volt, mik\u00f6zben a laborat\u00f3riumi vizsg\u00e1latok t\u00f6bb Omikron-alvonal, k\u00f6zt\u00fck a KP.3, XEC \u00e9s LP.8.1 jelenl\u00e9t\u00e9t is igazolt\u00e1k.<\/p>\n

Vizsg\u00e1latunk c\u00e9lja annak felm\u00e9r\u00e9se volt, hogy a 2024\/25 \u00e9vi szezonban alkalmazott Covid-19 olt\u00e1sok milyen m\u00e9rt\u00e9kben v\u00e9dt\u00e9k meg az id\u0151sebb eur\u00f3pai lakoss\u00e1got a SARS-CoV-2 okozta, k\u00f3rh\u00e1zi kezel\u00e9st ig\u00e9nyl\u0151 s\u00falyos lefoly\u00e1s\u00fa fert\u0151z\u00e9st\u0151l. A kutat\u00e1s hat orsz\u00e1g t\u00f6bb k\u00f3rh\u00e1z\u00e1ban zajlott, s\u00falyos akut l\u00e9g\u00fati megbeteged\u00e9ssel (SARI) k\u00f3rh\u00e1zi ell\u00e1t\u00e1st ig\u00e9nyl\u0151, 60 \u00e9ves \u00e9s id\u0151sebb szem\u00e9lyek k\u00f6z\u00f6tt. A vizsg\u00e1latot teszt-negat\u00edv, eset-kontroll m\u00f3dszerrel v\u00e9gezt\u00fck, \u00f6sszesen 352 SARS-CoV-2 PCR-pozit\u00edv eset \u00e9s 9\u00a0980 hozz\u00e1juk rendelt kontroll bevon\u00e1s\u00e1val. Az esetek 33%-a, m\u00edg a kontrollok fele r\u00e9szes\u00fclt valamely Covid-19 olt\u00e1sban. A v\u00e9d\u0151olt\u00e1s-eredm\u00e9nyess\u00e9get (VE) statisztikai m\u00f3dszerekkel sz\u00e1m\u00edtottuk, az eredm\u00e9nyeket \u00e9letkorra, nemre, kr\u00f3nikus betegs\u00e9gekre, a vizsg\u00e1lati helysz\u00ednre, valamint a t\u00fcnetek megjelen\u00e9sek d\u00e1tum\u00e1ra korrig\u00e1ltuk.<\/p>\n

A 60 \u00e9vesek \u00e9s id\u0151sebbek k\u00f6r\u00e9ben az olt\u00e1st k\u00f6vet\u0151 14-59 napban 42%-os, 60-119 napban 32%-os, m\u00edg 120-179 napban 36%-os VE-t m\u00e9rt\u00fcnk. 180 nappal az olt\u00e1s ut\u00e1n azonban m\u00e1r nem volt kimutathat\u00f3 v\u00e9detts\u00e9g. A 60-79 \u00e9ves koroszt\u00e1lyban m\u00e9rs\u00e9kelt VE-t m\u00e9rt\u00fcnk, a v\u00e9delem legfeljebb k\u00e9t h\u00f3napon kereszt\u00fcl tartott, m\u00edg a 80 \u00e9v felettiek eset\u00e9ben a v\u00e9detts\u00e9g ak\u00e1r n\u00e9gy h\u00f3napon kereszt\u00fcl fennmaradt.<\/p>\n

Eredm\u00e9nyeink azt mutatj\u00e1k, hogy a szezon\u00e1lis Covid\u201119 olt\u00e1s az id\u0151sebb koroszt\u00e1lyban m\u00e9rs\u00e9kelt v\u00e9delmet ny\u00fajtott a s\u00falyos megbeteged\u00e9st okoz\u00f3 fert\u0151z\u00e9sekkel szemben, amely az els\u0151 60 napban minden vizsg\u00e1lt korcsoportban kimutathat\u00f3 volt. A v\u00e9delem a 60-79 \u00e9vesekn\u00e9l gyorsabban cs\u00f6kkent, m\u00edg a 80 \u00e9v felettiek eset\u00e9ben tov\u00e1bb fennmaradt. A folyamatos v\u00e9delem biztos\u00edt\u00e1sa \u00e9rdek\u00e9ben javasolt az eml\u00e9keztet\u0151 d\u00f3zisok alkalmaz\u00e1sa, \u00e9s sz\u00fcks\u00e9g szerint tov\u00e1bbi j\u00e1rv\u00e1ny\u00fcgyi int\u00e9zked\u00e9sek bevezet\u00e9se, mint \u00f3vint\u00e9zked\u00e9sek (pl. maszkhaszn\u00e1lat) vagy c\u00e9lzott prevenci\u00f3s strat\u00e9gi\u00e1k form\u00e1j\u00e1ban.<\/p>\n

    \n
  1. \u00e1<\/strong>bra: <\/strong>A Covid-19 elleni olt\u00e1s eredm\u00e9nyess\u00e9ge a k\u00f3rh\u00e1zi kezel\u00e9st ig\u00e9nyl\u0151 megbeteged\u00e9sek megel\u0151z\u00e9s\u00e9ben id\u0151sebb feln\u0151ttek k\u00f6r\u00e9ben, VEBIS k\u00f3rh\u00e1zi h\u00e1l\u00f3zat, Eur\u00f3pa, 2024. szeptember \u2013 2025. m\u00e1jus<\/strong><\/span><\/li>\n<\/ol>\n

    \"\"<\/p>\n

    A Covid-19 vakcin\u00e1k eredm\u00e9nyess\u00e9ge a k\u00f3rh\u00e1zi ell\u00e1t\u00e1st ig\u00e9nyl\u0151 megbeteged\u00e9sek megel\u0151z\u00e9s\u00e9ben SARI-betegek k\u00f6r\u00e9ben, az olt\u00e1s \u00f3ta eltelt id\u0151 (60 napos bont\u00e1s) \u00e9s korcsoport (\u2265 60, 60\u201379 \u00e9s \u2265 80 \u00e9vesek) szerint. (n = 10 332)
    \n<\/span>2024. \u0151szi olt\u00e1si kamp\u00e1ny, VEBIS k\u00f3rh\u00e1zi vizsg\u00e1lat, Eur\u00f3pa, 2024. szeptember 29. \u2013 2025. m\u00e1jus 4.
    \n<\/span>CI: konfidencia intervallum; IQR: interkvartilis tartom\u00e1ny; TSV: az olt\u00e1s \u00f3ta eltelt id\u0151 (napok sz\u00e1ma az utols\u00f3 Covid-19 d\u00f3zist\u00f3l az els\u0151 t\u00fcnet megjelen\u00e9s\u00e9ig); VE: v\u00e9d\u0151olt\u00e1s-eredm\u00e9nyess\u00e9g; sz\u00fcrke jel\u00f6l\u00e9s: b\u00e1rmennyi id\u0151 az olt\u00e1s \u00f3ta.
    \n<\/span>Forr\u00e1s: Influenza Resp Viruses, Volume: 19, Issue: 11, First published: 25 November 2025, DOI: (10.1111\/irv.70191) publik\u00e1ci\u00f3 2. \u00e1br\u00e1ja alapj\u00e1n SE ESK saj\u00e1t szerkeszt\u00e9s<\/span><\/p>\n

    \u00a0<\/h3>\n

    Early COVID-19 XBB.1.5 Vaccine Effectiveness Against Hospitalisation Among Adults Targeted for Vaccination, VEBIS Hospital Network, Europe, October 2023-January 2024<\/strong><\/h3>\n

    Madelyn Rojas-Castro<\/em> (Epiconcept, Paris, France)
    \nGerg\u0151 T\u00fari <\/em>(National Laboratory for Health Security, Epidemiology and Surveillance Centre, Semmelweis University, Budapest)
    \nBeatrix Oroszi <\/em>(National Laboratory for Health Security, Epidemiology and Surveillance Centre, Semmelweis University, Budapest)
    \nVikt\u00f3ria Velkey <\/em>(National Laboratory for Health Security, Epidemiology and Surveillance Centre, Semmelweis University, Budapest)
    \nand the European Hospital Vaccine Effectiveness Group<\/em><\/p>\n

    Abstract<\/strong><\/h5>\n

    We estimated COVID\u201019 vaccine effectiveness (VE) against PCR\u2010confirmed SARS\u2010CoV\u20102 hospitalization in patients \u2265\u200960\u2009years with severe acute respiratory infection, using a multicenter, test\u2010negative, case\u2013control study across seven sites in six European countries between September 2024 and May 2025. We included 352 cases (115 vaccinated; 33%) and 9980 controls (5024 vaccinated; 50%). VE was 42% (95% CI: 15; 61) 14\u201359\u2009days post\u2010vaccination, 32% (95% CI: \u22121; 54) at 60\u2013119\u2009days, and 36% (95% CI: 2; 60) at 120\u2013179\u2009days, and no effect thereafter. Among adults aged 60\u201379 and \u2265\u200980\u2009years, we observed moderate VE against COVID\u201019 hospitalization for up to 2 and 4\u2009months, respectively.<\/p>\n

    * Vaccine Effectiveness, Burden and Impact Studies<\/span><\/p>\n

    Rojas-Castro M, Verdasca N, Monge S, De Mot L, Trobajo-Sanmart\u00edn C, Duffy R, T\u00fari G, Kuliese M, Duerrwald R, Borg ML, Popovici O, Gomez V, Makari\u0107 ZL, Launay O, Marques DFP, Pozo F, Witdouck A, Mart\u00ednez-Baz I, Fitzgerald M, Oroszi B, Jan\u010dorien\u0117 L, Buda S, Dziugyte A, Laz\u0103r M, Machado A, Tabain I, Nguyen LBL, Wagner ER, Dufrasne F, Castilla J, Domegan L, Velkey V, Majauskaite F, Hackmann C, Nicolay N, Bacci S, Rose AMC. COVID-19 Vaccine Effectiveness Against Hospitalization in Older Adults, VEBIS Hospital Network, Europe, September 2024-May 2025. Influenza Other Respir Viruses. 2025 Nov;19(11):e70191. doi: 10.1111\/irv.70191. PMID: 41290396; PMCID: PMC12646827.<\/span><\/p>\n

    https:\/\/pubmed.ncbi.nlm.nih.gov\/41290396\/<\/strong><\/a><\/p>\n

    K\u00e9sz\u00edtette az \"\"\u00a0<\/em><\/span><\/p>\n

    \"\"<\/em>RRF-2.3.1-21-2022-00006\u00a0<\/span><\/span><\/p>\n

    \"\"<\/b><\/p>\n","protected":false},"excerpt":{"rendered":"

    VEBIS* k\u00f3rh\u00e1zi h\u00e1l\u00f3zat, Eur\u00f3pa, 2024. szeptember \u2013 2025. m\u00e1jus 2024. \u0151sz\u00e9n a 60 \u00e9v felettiek \u00e9s m\u00e1s magas kock\u00e1zat\u00fa c\u00e9lcsoportok Covid-19 elleni v\u00e9delm\u00e9re olt\u00e1si kamp\u00e1nyokat ind\u00edtottak Eur\u00f3p\u00e1ban. Els\u0151dleges olt\u00f3anyagk\u00e9nt ebben az id\u0151szakban a Comirnaty Omikron JN.1 vakcin\u00e1j\u00e1t alkalmazt\u00e1k, ezzel a c\u00e9lcsoportok \u00e1toltotts\u00e1ga az egyes orsz\u00e1gokban alacsony, m\u00edg m\u00e1shol k\u00f6zepes volt. A szezon sor\u00e1n a SARS\u2011CoV\u20112 …<\/p>\n","protected":false},"author":102284,"featured_media":2327,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[9],"tags":[],"class_list":["post-2326","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cikk-osszefoglalok"],"acf":[],"_links":{"self":[{"href":"https:\/\/semmelweis.hu\/esk\/wp-json\/wp\/v2\/posts\/2326","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/semmelweis.hu\/esk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/semmelweis.hu\/esk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/semmelweis.hu\/esk\/wp-json\/wp\/v2\/users\/102284"}],"replies":[{"embeddable":true,"href":"https:\/\/semmelweis.hu\/esk\/wp-json\/wp\/v2\/comments?post=2326"}],"version-history":[{"count":1,"href":"https:\/\/semmelweis.hu\/esk\/wp-json\/wp\/v2\/posts\/2326\/revisions"}],"predecessor-version":[{"id":2328,"href":"https:\/\/semmelweis.hu\/esk\/wp-json\/wp\/v2\/posts\/2326\/revisions\/2328"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/semmelweis.hu\/esk\/wp-json\/wp\/v2\/media\/2327"}],"wp:attachment":[{"href":"https:\/\/semmelweis.hu\/esk\/wp-json\/wp\/v2\/media?parent=2326"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/semmelweis.hu\/esk\/wp-json\/wp\/v2\/categories?post=2326"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/semmelweis.hu\/esk\/wp-json\/wp\/v2\/tags?post=2326"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}